http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114487431-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0a90153da9a4932844c7beef3965261 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54306 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N27-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate | 2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2158ecbf559a949bd58732807f89097a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84fcc23930e76484024de7605c1561a4 |
| publicationDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114487431-A |
| titleOfInvention | Application of urinary α-2-HS-glycoprotein and its polypeptide fragments in gestational diabetes mellitus |
| abstract | The present invention provides an application of urine α-2-HS-glycoprotein (Alpha-2-HS-glycoprotein, AHSG) and polypeptide fragments thereof, in particular to urine α-2-HS-glycoprotein and its polypeptide fragments in The application of preparations for the diagnosis and treatment of gestational diabetes mellitus, monitoring, evaluation and mechanism research of blood glucose and metabolic state. The present invention confirms through research that urinary α-2-HS- glycoprotein and its polypeptide fragments increase with the increase of FPG level in patients with gestational diabetes mellitus. The difference in mmol/l GM2 group was statistically significant, and it can be used for various purposes such as diagnosis and treatment of gestational diabetes mellitus, monitoring, evaluation and mechanism research of blood glucose and metabolic state. The invention takes advantage of the advantages of non-invasive, large-scale repeated sampling, and convenient storage of urine specimens to detect α-2-HS-glycoprotein and its polypeptide fragments by utilizing the urine specimens. |
| priorityDate | 2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 252.